Top

Cancer Causes & Control

Published in:

01-12-2008 | Original Paper

Hypercholesterolemia and prostate cancer: a hospital-based case–control study

Authors: Lindsay Magura, Richelle Blanchard, Brian Hope, James R. Beal, Gary G. Schwartz, Abe E. Sahmoun

Published in: Cancer Causes & Control | Issue 10/2008

Abstract

Objective

High levels of serum cholesterol have been proposed to increase the risk of prostate cancer but the epidemiologic evidence is limited.

Methods

We conducted a hospital-based case–control study in Fargo, ND, USA, to examine the association between hypercholesterolemia and prostate cancer. Cases were men with incident, histologically confirmed prostate cancer. Controls were men without clinical cancer who were seen at the same hospital for an annual physical exam. Demographic and clinical data were abstracted from patients’ medical charts.

Results

From a patient population aged 50 to 74 years old, we obtained data on 312 White cases and 319 White controls. Hypercholesterolemia was defined as total cholesterol greater than 5.17 (mmol/l). Univariate logistic regression showed a significant association between hypercholesterolemia and prostate cancer (odds ratio (OR) = 1.64, 95% confidence interval (CI): 1.19–2.27). This association changed only slightly after adjustment for age, family history of prostate cancer, body mass index, type 2 diabetes, smoking, and multivitamin use (OR = 1.58, 95% CI: 1.11–2.24). A significant association was found between low HDL and prostate cancer (OR = 1.57, 95% CI: 1.04–2.36). High LDL was associated with a 60% increased risk for prostate cancer (OR = 1.60, 95% CI: 1.09–2.34). Compared to never smokers, current smokers had an 84% increased risk for prostate cancer (OR = 1.84, 95% CI: 1.09–3.13).

Conclusion

This study adds to recent evidence that hypercholesterolemia may increase the risk of prostate cancer in white men.

Jemal A, Siegel R, Ward E et al (2008) Cancer Statistics. CA Cancer J Clin 58(2):73CrossRef

Cox B, Sneyd MJ, Paul C et al (2002) Vasectomy and the risk of prostate cancer. JAMA 287:3110–3115. doi:10.1001/jama.287.23.3110 PubMedCrossRef

Dennis LK, Dawson DV (2002) Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 13:72–79. doi:10.1097/00001648-200201000-00012 PubMedCrossRef

Kirsh VA, Hayes RB, Mayne ST et al (2006) Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst 98:245–254PubMed

Chen C, Lewis SK, Voigt L et al (2005) Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103:76–84. doi:10.1002/cncr.20727 PubMedCrossRef

Giovannucci E, Rimm EB, Liu Y et al (2003) Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 95:1240–1244PubMed

Swyer G (1942) The cholesterol content of normal and enlarged prostates. Cancer Res 2:372–375

Homma Y, Kondo Y, Kaneko M et al (2004) Promotion of carcinogenesis and oxidative stress by dietary cholesterol in rat prostate. Carcinogenesis 25(6):1011–1014. doi:10.1093/carcin/bgh105 PubMedCrossRef

Sivaprasad U, Abbas T, Dutta A (2006) Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 5(9):2310–2316. doi:10.1158/1535-7163.MCT-06-0175 PubMedCrossRef

10.

Shibata MA, Kavanaugh C, Shibata E et al (2003) Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 24(3):453–459. doi:10.1093/carcin/24.3.453 PubMedCrossRef

11.

Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22(12):2388–2394. doi:10.1200/JCO.2004.02.027 PubMedCrossRef

12.

Bravi F, Scotti L, Bosetti C et al (2006) Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol 17(6):1014–1017. doi:10.1093/annonc/mdl080 PubMedCrossRef

13.

Hiatt RA, Fireman BH (1986) Serum cholesterol and the incidence of cancer in a large cohort. J Chronic Dis 39(11):861–870. doi:10.1016/0021-9681(86)90034-2 PubMedCrossRef

14.

Knekt P, Reunanen A, Aromaa A, Heliovaara M, Hakulinen T, Hakama M (1988) Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol 41(6):519–530. doi:10.1016/0895-4356(88)90056-X PubMedCrossRef

15.

Smith GD, Shipley MJ, Marmot MG, Rose G (1992) Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 267(1):70–76. doi:10.1001/jama.267.1.70 PubMedCrossRef

16.

Jacobs E, Rodriguez C, Bain EB, Wang Y, Thun M, Calle E (2007) Cholesterol lowering drugs and advanced prostate cancer incidence in a large United States cohort. Cancer Epidemiol Biomarkers Prev 16:2213–2217. doi:10.1158/1055-9965.EPI-07-0448 PubMedCrossRef

17.

Flick E, Habel L, Chan A et al (2007) Statin use and risk of prostate cancer in the California Men’s Health Study cohort. Cancer Epidemiol Biomarkers Prev 16:2218–2225. doi:10.1158/1055-9965.EPI-07-0197 PubMedCrossRef

18.

Murtola T, Tammela TLJ, Lahtela J, Auvinen A (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case–control study. Cancer Epidemiol Biomarkers Prev 16:2226–2232. doi:10.1158/1055-9965.EPI-07-0599 PubMedCrossRef

19.

Platz EA, Leitzmann MF, Visvanathan K et al (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98:1819–1825PubMedCrossRef

20.

Shannon J, Tewoderos S, Garzotto M et al (2005) Statins and prostate cancer risk: a case–control study. Am J Epidemiol 162(4):318–325. doi:10.1093/aje/kwi203 PubMedCrossRef

21.

Murtola TJ, Tammela TL, Lahtela J, Auvinen A (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case–control study. Cancer Epidemiol Biomarkers Prev 16:2226–2232. doi:10.1158/1055-9965.EPI-07-0599 PubMedCrossRef

22.

Bonovas S, Filioussi K, Sitaras NM (2008) Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 123:899–904. doi:10.1002/ijc.23550 PubMedCrossRef

23.

Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 106:3143

24.

Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR (2007) Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 16(3):416–421. doi:10.1158/1055-9965.EPI-06-0737 PubMedCrossRef

25.

Sonnleithner M, Jeschke K, Bayer L et al (2003) Dyslipoproteinemia as a risk factor in prostate cancer. J Urol 169(4):76CrossRef

26.

Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT (2004) Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13(10):1646–1650PubMed

27.

Hammarsten J, Hogstedt B (2004) Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 13(1):47–55. doi:10.1080/08037050310025735 PubMedCrossRef

28.

Tuohimaa P, Tenkanen L, Syvala H et al (2007) Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16(2):302–307. doi:10.1158/1055-9965.EPI-06-0777 PubMedCrossRef

29.

Hamalainen E, Adlercreutz H, Ehnholm C, Puska P (1986) Relationships of serum lipoproteins and apoproteins to sex hormones and to the binding capacity of sex hormone binding globulin in healthy Finnish men. Metabolism 35(6):535–541. doi:10.1016/0026-0495(86)90011-9 PubMedCrossRef

30.

Haffner SM, Valdez RA (1995) Endogenous sex hormones: impact on lipids, lipoproteins, and insulin. Am J Med 98(1A):40S–47S. doi:10.1016/S0002-9343(99)80058-8 PubMedCrossRef

31.

Shono N, Kumagai S, Higaki Y, Nishizumi M, Sasaki H (1996) The relationships of testosterone, estradiol, dehydroepiandrosterone-sulfate and sex hormone-binding globulin to lipid and glucose metabolism in healthy men. J Atheroscler Thromb 3(1):45–51PubMed

32.

33.

Key TJ, Allen N, Appleby P et al (2004) Fruits and vegetables and prostate cancer: no association among 1,104 cases in a prospective study of 130,544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 109(1):119–124. doi:10.1002/ijc.11671 PubMedCrossRef

34.

Stram DO, Hankin JH, Wilkens LR et al (2006) Prostate cancer incidence and intake of fruits, vegetables and related micronutrients: the multiethnic cohort study. Cancer Causes Control 17(9):1193–1207. doi:10.1007/s10552-006-0064-0 PubMedCrossRef

35.

Colli JL, Colli A (2006) International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. Urol Oncol 24(3):184–194. doi:10.1016/j.urolonc.2005.05.023 PubMed

36.

Cohen JH, Kristal AR, Stanford JL (2000) Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 92(1):61–68. doi:10.1093/jnci/92.1.61 PubMedCrossRef

37.

Jian L, Du CJ, Lee AH, Binns CW (2005) Do dietary lycopene and other carotenoids protect against prostate cancer? Int J Cancer 113(6):1010–1014. doi:10.1002/ijc.20667 PubMedCrossRef

38.

Lawson KA, Wright ME, Subar A et al (2007) Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst 99(10):754–764. doi:10.1093/jnci/djk177 PubMedCrossRef

39.

Stevens VL, McCullough ML, Diver WR et al (2005) Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 16(6):643–650. doi:10.1007/s10552-005-0384-5 PubMedCrossRef

40.

Centers for Disease Control and Prevention: Behavioral Risk Factor Surveillance System [www.cdc.gov/brfss]

41.

Schwartz GG (2005) Vitamin D and the epidemiology of prostate cancer. Semin Dial 18:276–289. doi:10.1111/j.1525-139X.2005.18403.x PubMedCrossRef

42.

Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE (1999) Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8(10):887–892PubMed

43.

Drasch G, Schopfer J, Schrauzer GN (2005) Selenium/cadmium ratios in human prostates: indicators of prostate cancer risk of smokers and nonsmokers, and relevance to the cancer protective effects of selenium. Biol Trace Elem Res 103(2):103–107. doi:10.1385/BTER:103:2:103 PubMedCrossRef

44.

Rohan TE, Hislop TG, Howe GR, Gallagher RP, Teh CZ, Ghadirian P (1997) Cigarette smoking and risk of prostate cancer: a population-based case–control study in Ontario and British Columbia, Canada. Eur J Cancer Prev 6(4):382–388. doi:10.1097/00008469-199708000-00011 PubMedCrossRef

45.

Singal V, Khurana V, Caldito G, Fort C (2005) Statins and prostate cancer risk: a large case–control study in Veterans. J Clin Oncol 23:107S

46.

Kaplan SA, Meehan AG, Shah A (2006) The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 176(4 Pt 1):1524–1527. doi:10.1016/j.juro.2006.06.003 PubMedCrossRef

47.

Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51(14):3748–3752PubMed

48.

http://apps.nccd.cdc.gov/brfss/sex.asp?cat=CA&yr=2005&qkey=4392&state=ND. Accessed on 21 May 2007

49.

http://apps.nccd.cdc.gov/BRFSS/page.asp?cat=XX&yr=2007&state= ND#XX. Accessed on 11 May 2008

50.

Cinci G, Pagani R, Pandolfi ML, Porcelli B, Pizzichini M, Marinello E (1993) Effects of testosterone on cholesterol levels and fatty acid composition in the rat. Life Sci 53(2):91–97. doi:10.1016/0024-3205(93)90655-M PubMedCrossRef

51.

Moorjani S, Dupont A, Labrie F et al (1988) Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab 66(2):314–322PubMedCrossRef

Title: Hypercholesterolemia and prostate cancer: a hospital-based case–control study
Authors: Lindsay Magura
Richelle Blanchard
Brian Hope
James R. Beal
Gary G. Schwartz
Abe E. Sahmoun
Publication date: 01-12-2008
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 10/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-008-9197-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2008

Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk

Childhood hematopoietic malignancies and parental use of tobacco and alcohol: the ESCALE study (SFCE)

Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer

Alcohol and risk of lung cancer among Japanese men: data from a large-scale population-based cohort study, the JPHC study

Anthropometric factors at age 20 years and risk of thyroid cancer

Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer